|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are used to ameliorate cancer therapy-induced neutropenia and mucositis.
|
16912178 |
2006 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Neutropenia and febrile neutropenia (FN) are serious side effects of cytotoxic chemotherapy which may be alleviated with the administration of recombinant granulocyte colony-stimulating factor (GCSF) derivatives, such as pegfilgrastim (PG) which increases absolute neutrophil count (ANC).
|
30112626 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Grade 4 neutropenia lasted for 10 days despite intensive G-CSF administration.
|
28789371 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review focuses on the key clinical finding and laboratory tests for diagnosis with commentaries on treatment, particularly the use of granulocyte colony-stimulating factor to treat childhood neutropenia.
|
28419427 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemotherapy determined also neutropenia that was treated by filgrastim, followed by a prompt and important medullary response.
|
29401143 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
During treatment, 60.0% (n=129) of participants received granulocyte colony-stimulating factor as secondary prophylaxis for neutropenia, a lower proportion on FCR compared with FCM-R (56.1 vs 63.9%).
|
28216660 |
2017 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exposure-safety analyses supported the recommended brentuximab vedotin starting dose (1.2 mg/kg every 2 weeks), and effective management of peripheral neuropathy and neutropenia with dose modification/reduction and febrile neutropenia with granulocyte colony-stimulating factor primary prophylaxis.
|
31152605 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
|
30043207 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
He responded well to filgrastim (Neupogen) and blood transfusions, so a drug-related cause of neutropenia has been suspected.
|
31142911 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony stimulating factor (G-CSF) regulates survival, proliferation, and differentiation of neutrophilic granulocyte precursors, Recombinant G-CSF has been used for the treatment of congenital and therapy-induced neutropenia and stem cell mobilization.
|
21668998 |
2011 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recurrent large, painful oral ulcerations can occur that are not necessarily associated with neutropenia nor do they respond to granulocyte colony-stimulating factor administration.
|
9486673 |
1998 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
We discuss the potential associations between neutropenia and gastrointestinal disease with FTT and the role of granulocyte colony-stimulating factor in improving neutrophil count and intestinal integrity and growth.
|
27571123 |
2016 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
|
29091995 |
2018 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Only one patient experienced grade 3 neutropenia (3%), two patients grade 3 anemia (6%), and one patient grade 3 fatigue (3%); three patients were treated with prophylactic Granulocyte colony-stimulating factor (9%).
|
31356228 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The duration of grade 2-4 neutropenia in cycles using filgrastim was significantly longer than that in those pegfilgrastim (p=0.01).
|
29936477 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte-colony stimulating factor (G-CSF) and pegylated G-CSF are used for the prevention of neutropenia after chemotherapy.
|
30181755 |
2018 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Possible intervention is to administer drugs that raise neutrophil count such as filgrastim before neutropenia occurs.
|
29574886 |
2018 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Multivariate analysis suggested that grade 4 neutropenia associated significantly with an hmz UGT1A1 genotype [odds ratio (OR) 11.3; P = 0.04] and administration of granulocyte colony-stimulating factor (G-CSF) before the neutrophil counts dropped to < 500 cells/µL (OR; P = 0.01).
|
30328531 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony stimulating factor (GCSF) is clinically used as a treatment for congenital and acquired neutropenia.
|
22427476 |
2012 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The associated neutropenia can be partially corrected by treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF).
|
10607719 |
2000 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
The use of granulocyte colony-stimulating factor can be beneficial to shorten the duration of neutropenia.
|
31842164 |
2020 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
This includes real-world data from MONITOR-GCSF, a multicenter, prospective, observational study describing treatment patterns and clinical outcomes of patients with cancer (n = 1447) receiving biosimilar filgrastim for the prophylaxis of chemotherapy-induced neutropenia in solid tumors and hematological malignancies.
|
31440986 |
2019 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Granulocyte colony-stimulating factor (G-CSF) is commonly used in patients with neutropenia.
|
30174163 |
2018 |
|
Neutropenia
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anemia and neutropenia were managed with Erythropoietin and Filgrastim supplementation, respectively.Only six patients discontinued therapy.
|
25469044 |
2014 |
|
Neutropenia
|
0.400 |
Biomarker
|
disease |
BEFREE |
Leukocyte integrin activation mediates transient neutropenia after G-CSF administration.
|
21844566 |
2011 |